Feb 12, 2020 2:15 pm EST Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
Jan 21, 2020 8:00 am EST Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
Jan 13, 2020 9:00 am EST Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Dec 24, 2019 1:01 pm EST Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dec 20, 2019 9:23 am EST Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants
Dec 20, 2019 8:26 am EST Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
Dec 19, 2019 5:20 pm EST Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
Dec 9, 2019 8:45 am EST Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Nov 12, 2019 4:30 pm EST Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
